GC Therapeutics secures $65m to launch into off-the-shelf iPSC therapy space
The biotech has secured $65m in a Series A funding round led by Cormorant Asset Management and other investors.
The biotech has secured $65m in a Series A funding round led by Cormorant Asset Management and other investors.
What's Your Reaction?
